Department of Vaccine Evaluation, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
Clinical Research Department, Sinovac Biotech Co., Ltd., Beijing, China.
Expert Rev Vaccines. 2021 Jun;20(6):761-767. doi: 10.1080/14760584.2021.1919091. Epub 2021 May 16.
: Sabin strain inactivated poliovirus vaccine (sIPV) developed by Sinovac Biotech Co., Ltd., has shown good safety and immunogenicity against parental strains among infants in several finished pre-licensure clinical trials.: To further study the neutralizing capacity of investigational sIPV immune serum against Sabin, Salk and recently circulating poliovirus strains, neutralization assay against ten individual strains was performed on backup serum collected from 250 infant participants of the finished phase II clinical trial.: The sIPV can generate good immunogenicity against Sabin, Salk and recently circulating poliovirus strains. Taking into account its lower containment requirements and financial costs compared with the conventional Salk strain inactivated poliovirus vaccine, sIPV is an affordable and practical option for polio eradication.
: 由科兴生物制药有限公司开发的沙宾株灭活脊髓灰质炎病毒疫苗（sIPV），在几项已完成的上市前临床试验中，显示出对婴儿原始脊灰病毒株良好的安全性和免疫原性。
: 为了进一步研究受试 sIPV 免疫血清对沙宾、索尔克和最近流行的脊灰病毒株的中和能力，对 250 名完成 II 期临床试验的婴儿参与者的备份血清进行了针对十种单株的中和测定。
: sIPV 可以对沙宾、索尔克和最近流行的脊灰病毒株产生良好的免疫原性。考虑到与传统的 Salk 株灭活脊灰病毒疫苗相比，sIPV 的控制要求和经济成本较低，因此 sIPV 是消灭脊灰的一种经济实惠且实用的选择。
